Reg Capital Advisors

Oleg Nodelman, the firm's founder and managing partner, is the sole decision-maker. The firm operates as a single-family office with a concentrated public-equities strategy, and all 13D filings and board-level engagements trace back to Nodelman directly.

It is structured as a family office, meaning it deploys permanent capital that is not subject to external redemption demands. However, its strategy mimics an activist hedge fund — it files Schedule 13Ds, seeks board seats, and pushes for operational changes in clinical-stage biotechnology companies.

The firm concentrates on small- and micro-cap biotechnology, healthcare services, and life-sciences tools companies, primarily in North America and Europe. It seeks deeply underperforming or mismanaged issuers where a governance push can unlock value through restructured clinical programs, licensing deals, or asset sales.

Reg Capital's disclosed activity has been in publicly traded equities — the firm's activist model relies on SEC filing requirements to pressure management. It has participated in discounted bridge financings for microcap issuers, but a dedicated private-venture arm has not been disclosed.

Nodelman sources opportunities through deep domain specialization rather than a broad institutional pipeline. His firm screens for clinical-stage companies with depressed market values but viable drug candidates, particularly where existing management has lost shareholder confidence and a catalytic event — a clinical readout, a licensing negotiation, or a financing deadline — can be expedited by new board-level oversight.